The concept of hepatitis B virus mutant escape

被引:68
作者
Pawlotsky, Jean-Michel [1 ]
机构
[1] Univ Paris 12, Hop Henri Mondor, INSERM, Dept Virol,U635, F-94010 Creteil, France
关键词
HBV lifecycle; HBV variability; Escape mutant;
D O I
10.1016/S1386-6532(05)80021-6
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis B virus (HBV) reverse transcriptase is an error-prone enzyme, and this results in a large number of nucleotide substitutions during replication. As a result, HBV has a "quasispecies" distribution in infected individuals, meaning that HBV circulates as a complex mixture of genetically distinct but closely related variants that axe in equilibrium at a given time point of infection in a given replicative environment. The quasispecies distribution of HBV implies that any newly generated mutation conferring a selective advantage to the virus in a given replicative environment will allow the corresponding viral population to overtake the other variants. Such selection processes occur at any step of infection to allow the emergence of variant viruses, such as precore and core promoter mutants during the natural course of infection, HBs antigen mutants under the pressure of active or passive anti-HBs immunization, or HBV mutants that are resistant to the antiviral action of specific HBV inhibitors. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:S125 / S129
页数:5
相关论文
共 48 条
[1]   Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].
Allen, MI ;
Deslauriers, M ;
Andrews, CW ;
Tipples, GA ;
Walters, KA ;
Tyrrell, DLJ ;
Brown, N ;
Condreay, LD .
HEPATOLOGY, 1998, 27 (06) :1670-1677
[2]   Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].
Angus, P ;
Vaughan, R ;
Xiong, S ;
Yang, HL ;
Delaney, W ;
Gibbs, C ;
Brosgart, C ;
Colledge, D ;
Edwards, R ;
Ayres, A ;
Bartholomeusz, A ;
Locarnini, S .
GASTROENTEROLOGY, 2003, 125 (02) :292-297
[3]   YSDD:: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine [J].
Bozdayi, AM ;
Uzunalimoglu, Ö ;
Türkyilmaz, AR ;
Aslan, N ;
Sezgin, O ;
Sahin, T ;
Bozdayi, G ;
Çinar, K ;
Pai, SB ;
Pai, R ;
Bozkaya, H ;
Karayalçin, S ;
Yurdaydin, C ;
Schinazi, RF .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) :256-265
[4]  
Cane PA, 1999, ANTIVIR THER, V4, P7
[5]  
CARMAN WF, 1989, LANCET, V2, P588
[6]   The clinical significance of surface antigen variants of hepatitis B virus [J].
Carman, WF .
JOURNAL OF VIRAL HEPATITIS, 1997, 4 :11-20
[7]  
Chang TT, 2004, HEPATOLOGY, V40, p193A
[8]   In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil [J].
Chin, R ;
Shaw, T ;
Torresi, J ;
Sozzi, V ;
Trautwein, C ;
Bock, T ;
Manns, M ;
Isom, H ;
Furman, P ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2495-2501
[9]  
Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
[10]   Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study A1463-014 [J].
Colonno, R ;
Rose, R ;
Cross, A ;
Hindes, R ;
Tenney, D .
JOURNAL OF HEPATOLOGY, 2004, 40 :16-16